Baird maintains InMode at Neutral, lowers price target to $15 from $17
Baird kept InMode at Neutral but reduced its price target to $15 from $17, an 11.8% cut. The new target suggests 9.2% upside from the Nov 11 close of $13.73, according to the firm.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short-term selling, but the stock remains above the new target, leaving upside potential if fundamentals improve.
Market read
A modest analyst downgrade with limited immediate market impact.
What to watch
Potential upcoming product approvals or contract wins not reflected in the target change.
Background
Baird's analyst report provides a revised valuation for InMode, a minimally invasive aesthetic medical device maker.
Ticker impact
Baird lowered its price target for InMode to $15 from $17, indicating a fresh downgrade.
likely pressure as the market prices in the lower target
Analyst target cuts often lead to short-term sell pressure, especially when the new target is below current price.
Market effects
Minimal impact on the broader medical device sector.
Limited to U.S. markets where INMD trades.
Low global relevance.
Counterpoint
The target cut may be overly cautious; the stock could rebound if upcoming data exceeds expectations.
Key entities
- CompanyInMode
Medical device company listed on NASDAQ (INMD).
- AnalystBaird
Equity research firm issuing the price target revision.
